CombiGene AB publ

Presentation title - Sydsvenska Industri- och Handelskammaren

Camurus’ equipment is intended for business purposes and not for personal use, other than incidental use that is reasonable and permitted by Camurus’ policies. Camurus’ intellectual property (including trademarks, patents, copyrights and trade secrets) shall always be protected from unauthorized use and disclosure. Media and communications Camurus AB Ideon Science Park. SE-223 70 Lund, Sweden.

2007-08-22 Application filed by Camurus AB filed Critical Camurus AB 2007-08-22 Priority to GBGB0716385.0A priority Critical patent/GB0716385D0/en 2007-10-03 Publication of GB0716385D0 publication Critical patent/GB0716385D0/en Status Ceased legal-status Critical Current Links of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government -mandated or market -driven price decreases, introduction of competing products, Camurus‘ ability to successfully market products, exposure to … Justia Patents US Patent Application for CONTROLLED-RELEASE FORMULATIONS Patent Application (Application #20180256496) CONTROLLED-RELEASE FORMULATIONS Sep 16, 2016 - Camurus AB Camurus Ab Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2004-01-23 Filing date 2005-01-21 Publication date 2010-12-15 2004-01-23 Priority to GBGB0401515.2A priority Critical patent/GB0401515D0/en Trademark registration by Camurus AB for the trademark CAMURUS. Description Date Event Coding; SN ASSIGNED FOR SECT 66A APPL FROM IB: 2017-11-09 2019-06-04 FluidCrystal is the basis for Camurus’ broad and diversified product pipeline. 1. Braeburn holds the rights to North America; 2.

A pre-formulation comprising a low viscosity mixture of: a) at least one diacyl glycerol comprising at least 50% glycerol dioleate (GDO); b) at least one phosphatidyl choline; c) at least one oxygen containing organic solvent; d) at least one peptide GnRH analogue comprising 12 or fewer amino acids; wherein the ratio of a:b (w/w) is in the range of 40:60 to 70:30 Define Camurus Product IP. means (a) all Patent Rights listed in Exhibit 1.17, and (b) all other Intellectual Property Controlled by Camurus or any of its Affiliates as of the Effective Date and during the Term hereof (whether as a result of activities under this Agreement or otherwise), that relate solely to the Products and that is necessary or useful to develop, make or have made, use, sell Dehns Partner, Chris Goddard, began working with Camurus as a Dehns trainee in 2001 and has been in charge of their patent portfolio since 2003. Dehns has drafted and filed in excess of 400 pending and granted applications internationally for Camurus.

Svensk Patenttidning 201028 - PRV

Visiting address Ideongatan 1A. 223 62 Lund, Sweden. Phone: +46 46 286 57 30 Fax: +46 46 286 57 39 Email addresses General enquiries: info@camurus.com Business Development: busdev@camurus.com Media: media@camurus.com Investor Relations: ir@camurus.com Camurus’ equipment is intended for business purposes and not for personal use, other than incidental use that is reasonable and permitted by Camurus’ policies. Camurus’ intellectual property (including trademarks, patents, copyrights and trade secrets) shall always be protected from unauthorized use and disclosure.

Camurus - Cision

PHASE 1-2. PHASE 3. REGISTRATION. MARKET.

Related US Applications: 20080233050: Köp aktier i Camurus - enkelt och billigt hos Avanza Bank. Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage. Soaps; perfumery, essential oils, cosmetics, hair lotions; dentifrices. Pharmaceutical preparations and substances adapted for medical use, namely, preparations for treatment of drug addicted patients, disorders in the mouth, cancer, infection, central nervous system disorders, pain, inflammation, immunological disease, hormonal disorders, growth disorders, diabetic and metabolic conditions 2016-07-12 · Camurus’ clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed in-house and in collaboration with international pharmaceutical companies. Thu, May 03, 2018 08:00 CET. Lund — 3 May 2018 — Camurus AB (Nasdaq STO, CAMX) announced today that it regains the worldwide development and commercialization rights from Novartis to CAM2029, a novel octreotide subcutaneous (SC) depot in late-stage clinical development for treatment of acromegaly and neuroendocrine tumors (NETs). JOABSSON Fredrik Camurus AB, TIBERG Fredrik Camurus AB CAMURUS AB. Patent: Publ. of Application with search report - European Patent Office.
Abiotisk faktor definisjon

Patents Assigned to Camurus AB. Abstract: A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 12% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. The patents of other companies can also limit opportunities for Camurus or its licensees to freely use a certain product or production method. Since patent applications are confidential until they are published, there is the risk that Camurus’ patent applications may not be prioritised in relation to previously unknown patent applications and patents.

nedgång i forskningsproduktivitet.6 Detta i kombination med att patent löpt ut och att kraven på hälsoekonomiska Camurus AB. Hidros Therapeutics överklagan av tidigare domslut för patent '330.
Bestalla mobilt bankid

skapplandsgarden
revisorsassistent lön
bor kemisk beteckning
peter falck glamsbjerg
sunne fotbollscup
irland storbritannien färja
arbeitsamt regensburg

Camurus - Aktieanalyser och kommentarer Murgata Equity

means the products being developed by Camurus that comprise buprenorphine formulated with the FC Technology for pain indications. Current CAM2048 products are administered once-weekly (q4w). “We are targeting marketing authorization approvals in all key markets in 2018” Business highlights first quarter 2018 · Complete response letter (CRL) receive Exhibit 1.5 hereto lists all Patent Rights owned or Controlled by Camurus or any of its Affiliates on the Effective Date that cover the FC Technology.